GLP1_NEW
MEDI4166 50 mg injection once weekly
MEDI41_SC_50MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.76 (0.01 to 58.31) | 0.53 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.63 (0.09 to 20.95) | 0.57 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.55 (0.56 to 11.79) | 0.32 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.70 (0.05 to 5.85) | 0.67 |